Testing effectiveness (Phase 2)Study completedNCT05661578
What this trial is testing
Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors
Who this might be right for
PD-L1-selected Solid Tumors
Hoffmann-La Roche 64